Search Results

Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced it has signed an agreement with Janssen Research & Development, LLC (Janssen).

MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the “Company” or “MustGrow”), and Janssen PMP, a division of Janssen Pharmaceutica NV, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (NYSE: JNJ) (“Janssen PMP”) are pleased to announce a significant expansion to their existing Exclusive Evaluation and Option Agreement

AbelZeta Pharma, Inc. announced an amendment of its worldwide collaboration and license agreement with Janssen Biotech, Inc., a Johnson & Johnson company.

Predicine, Inc., a leading molecular insights company, announced a collaboration with Janssen Pharmaceutica NV, a Johnson & Johnson company.

Purdue Pharma L.P. (“Purdue”) announced today that the Company has awarded an investigator-initiated research (IIR) grant to a team of researchers at The University of New Mexico (UNM) for the evaluation of nalmefene hydrochloride (HCl) injection 2mg/2mL (1mg/1mL) in the emergency department setting.

Daxor Corporation today announces the appointment of Dr. John L. Jefferies, M.D., M.B.A., M.P.H., F.A.C.C., F.A.H.A., F.A.A.P., F.H.F.S.A., F.E.S.C., F.R.C.P.E., as Chief Medical Officer.

Cidara Therapeutics, Inc. has announced that Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, has delivered to Cidara its Election to Proceed Notice for CD388 (JNJ-0953) which is being developed for the universal prevention of influenza A and B.

Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. have entered into a binding settlement agreement and mutual release settling ongoing litigation.